Dr. Rick Press, director of molecular pathology at KDL’s Molecular Diagnostics Center was interviewed by the Portland Business Journal about the FDA’s plans to increase oversight of LDTs.

http://www.bizjournals.com/portland/blog/health-care-inc/2016/07/why-one-ohsu-geneticist-is-wary-of-steppedup-fda.html?ana=e_ptl_hc&u=lhGExavqGojJ1YFK0c1TxL/w8qI&t=1468890686&j=74838702